Impact of new TKIs on NSCLC treatment planning

Impact of new TKIs on NSCLC treatment planning

VJOncology

1 year
158 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Several generations of tyrosine kinase inhibitors (TKIs) have now been produced and examined for the treatment of EGFR mutant non-small cell lung cancer (NSCLC). Here, Nicolas Girard, MD, PhD, of Claude Bernard University, Lyon, France, discusses the different TKI treatment options at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland. He explores the varied benefits of gefitinib, erlotinib, afatinib and osimertinib, as well as the results of the FLAURA trial (NCT02296125), and the implications of these data on treatment sequencing.
Up Next Autoplay
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Category: Kidney Cancer
0 Views
kidneycancer 4 hours
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Category: Kidney Cancer
0 Views
kidneycancer 4 hours
Using Epigenetic Therapy to Enhance Immunotherapy Response in RCC
Using Epigenetic Therapy to Enhance Immunotherapy Response in RCC
Category: Kidney Cancer
1 Views
kidneycancer 4 hours
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
0 Views
kidneycancer 4 hours
Therapeutic targeting of the extracellular matrix in kidney cancer
Therapeutic targeting of the extracellular matrix in kidney cancer
Category: Kidney Cancer
0 Views
kidneycancer 4 hours
Innate Cytokines and Myeloid Cells
Innate Cytokines and Myeloid Cells
Category: Kidney Cancer
0 Views
kidneycancer 4 hours
DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells
DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells
Category: Kidney Cancer
0 Views
kidneycancer 4 hours
The T-cell response to Kidney Cancer
The T-cell response to Kidney Cancer
Category: Kidney Cancer
0 Views
kidneycancer 5 hours
Discovery of new IO Targets Leveraging CRISPR
Discovery of new IO Targets Leveraging CRISPR
Category: Kidney Cancer
1 Views
kidneycancer 5 hours
Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes
Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes
Category: Kidney Cancer
2 Views
kidneycancer 5 hours